Welcome to our dedicated page for Stereotaxis SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. completed its acquisition of French vascular robotics company Robocath for approximately $20 million in cash and common stock. As part of the deal, Stereotaxis issued 1,469,485 shares of common stock and pre-funded warrants to purchase 4,575,143 additional shares to Robocath securityholders.
The company also issued 225,000 shares to Robocath’s financial advisor as part of its success fee and may issue further stock or warrants tied to earnout milestones of up to $25.0 million. Any shares issued in connection with the acquisition will not exceed 19.9% of pre-transaction shares outstanding without stockholder approval. Stereotaxis plans to file a resale registration statement covering the stock consideration and an estimate of earnout-related shares.
SHAMIR NACHUM reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director Shamir Nachum reported an equity compensation grant in the form of restricted share units tied to the company’s common stock. The award covers 43,103 restricted share units, each representing one future share, granted at a stated price of $0.00 per share as typical for compensation grants.
Following this award, Nachum’s direct holdings increased to 179,327 shares of common stock. The restricted share units vest on the earliest of three events: the fifth anniversary of the award date, the director’s departure from the board, or a defined Change of Control, aligning vesting with long-term service or a major corporate event.
Benfer David reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director David Benfer reported an equity compensation grant, not an open-market trade. He received 43,103 restricted share units, each convertible into one share of common stock, at a price of $0.00 per share. The footnote states these restricted share units vest immediately on the grant date, so they effectively become common shares right away.
Following the grant, Benfer directly holds 558,975 shares of Stereotaxis common stock. He also has indirect ownership interests, including 210,255 shares held by the Benfer Family Trust and 2,700 shares held by his spouse as of the same date.
Levin Ross B reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director Ross B. Levin reported a grant of 43,103 restricted share units, each representing one share of common stock. These units vest on the earliest of the fifth anniversary of the award date, the end of his board service, or a defined Change of Control. Following this award, Levin directly holds 621,248 shares of common stock.
Curet Myriam reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director Myriam Curet reported receiving an equity award of 43,103 restricted share units, each representing one share of common stock. The grant was made at no cash cost to her and increased her directly owned stake to 435,161 shares.
The restricted share units vest on the earliest of the fifth anniversary of the award date, the end of her board service, or a defined Change of Control event, aligning her compensation with the company’s long-term performance and governance outcomes.
Fischel Nathan reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director and ten percent owner Nathan Fischel reported a grant of 43,103 restricted share units of common stock. The award has a grant price of $0.00 per unit, reflecting a compensation-related equity grant rather than an open-market purchase.
These restricted share units vest on the earliest of the fifth anniversary of the award date, the end of his board service, or a defined Change of Control. Following this grant, Fischel holds 720,775 shares of common stock directly. A separate line shows 13,680,554 shares held indirectly by funds managed by DAFNA Capital Management LLC, where he serves as Chief Executive Officer.
Menawat Arun Swarup reported acquisition or exercise transactions in this Form 4 filing.
Stereotaxis, Inc. director Arun Swarup Menawat received an equity grant of 43,103 shares of Common Stock as a compensation award. The shares were granted at no cash cost to him and increased his direct holdings to 1,035,560 shares following the transaction.
The award is structured as restricted share units, each convertible into one share of common stock. These units vest on the earliest of the fifth anniversary of the award date, the end of his board service, or a defined Change of Control, which ties the compensation to long-term service and corporate outcomes.
Stereotaxis, Inc. ownership filing by Lagoda Investment Management, L.P. Lagoda reports beneficial ownership of 4,350,400 shares of common stock as of March 31, 2026, representing 4.5% of the class. The filing cites 97,477,538 shares outstanding as of March 16, 2026 from the issuer's proxy statement. Lagoda's general partner structure and voting/dispositive authority are described, and the filing is signed by Jason A. Ozone on May 15, 2026.
Stereotaxis, Inc. reported the results of its May 14, 2026 Annual Meeting of Shareholders. A total of 97,477,538 common shares were entitled to vote, and Series A Convertible Preferred Stock carried 23,705,445 votes on an as-converted basis, for 121,182,983 total voting power. Quorum was achieved with 79,183,920 votes represented, about 65.34% of voting power.
Shareholders elected three Class I directors to serve until the 2029 annual meeting. David Benfer, Arun Menawat, and Myriam Curet each received between 49,544,105 and 52,711,903 votes for, with relatively low opposition. Shareholders also ratified Ernst & Young LLP as independent auditor for fiscal 2026 by 79,036,638 votes for versus 112,633 against and approved, on a non-binding basis, executive compensation with 52,143,334 votes for and 985,434 against.
Stereotaxis, Inc. reported a Q1 2026 net loss of $5.9M, similar to the prior year, as it continues investing in robotic cardiac and endovascular technologies. Revenue declined to $6.3M from $7.5M, with lower systems and disposable sales partly offset by higher service and accessories.
Operating expenses were $9.8M, roughly flat year over year, and basic and diluted net loss per share improved slightly to $0.06 from $0.07. Cash, cash equivalents, and restricted cash increased to $14.6M at March 31, 2026, helped by net proceeds of about $4.6M from an at-the-market stock offering.
The company signed an agreement on April 14, 2026 to acquire Robocath for $20.0M in cash and/or stock plus up to $25.0M in milestone-based contingent consideration, aiming to add mechanical robotic technology for interventional cardiology and neurointerventions. Stereotaxis also continues ramping its MAGiC and MAGiC Sweep catheters and faces macroeconomic, tariff, supply chain, and hospital capital spending headwinds while carrying an accumulated deficit of about $589.2M.